iPSC-derived pancreatic islet cell therapy (Laverock Therapeutics)

N/A

Report date: 2025/06/11 10:54:54

Base Information

Drug NameiPSC-derived pancreatic islet cell therapy (Laverock Therapeutics)
Drug Alias Namepancreatic islet cell therapy (Laverock Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Pancreatic stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLaverock Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLaverock Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A